Lines of business

Our businesses

Alvogen currently has commercial operations in 35 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania. Alvogen's lines of business include: product development, contract manufacturing and research (CMO), and sales of generic and brand medicines, biosimilars and OTC’s. Alvogen's product  portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology in addition to a fast growing portfolio of biosimilars and OTC products.  

Generics

We are building a strong profitable base and infrastructure for generic business in North America, Asia Pacific and Central and Eastern Europe. In the U.S., our portfolio is focused on niche generics, pathces, controlled release and narcotics.

Alvogen has 350 generic products on the market, with over 200 strategically selected development projects in the pipeline. Product formulations manufactured and sold by Alvogen include solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables. 

Marketed products
350
Commercial network
35

Biopharmaceuticals

Strong commitment for success in the fast paced and exciting new field of biosimilars. Through Alvogen’s sales network, the company is promoting and distributing a range of biosimilars in partnerships with third parties.

Alvogen’s sister company Alvotech is investing into the development of biosimilar monoclonal antibodies for key biologic molecules. The Alvotech – Alvogen alliance will strengthen Alvogen’s position as a key worldwide biosimilar player, promoting and distributing a variety of biosimilar products for many indications across several therapeutic areas.

Investment in biosimilars
$500m

Contract manufacturing

A long tradition of contract manufacturing for both originators as well as companies operating in the generic industry, through Alvogen's subsidiary, Norwich Pharma Services. With its 130-year history, the company provides contract manufacturing, product development and clinical services to third party customers. Norwich has a proven record of successfully meeting compliance requirements for regulatory agencies worldwide, including FDA, EMA and ANVISA.

Norwich capabilities finished dose form manufacturing and packaging include tablets, capsules, liquids, semi-solids and sponges.

Years of operations
130

OTC medicines

Tailor-made portfolio for each market based on local expertise and regional characteristics. Alvogen has hundreds of products in its growing OTC portfolio which promote a healthy lifestyle and offer innovative solutions to everyday problems. The products span four major categories: OTC medicines, food supplements, medical devices and cosmetics.

Over-The-Counter
100 +

portfolio items on market

Connect with local teams

Alvogen has commercial operations in 35 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania.

Alvogen has 350 generic products on the market, with over 200 strategically selected development projects in the pipeline. Connect with local teams to learn more about product offering in your region.

World offices